Sinovation (Beijing) Medical Technology Co., Ltd. is dedicated to the research, manufacturing, and technical services of intelligent innovative medical devices. As a leading enterprise in neurosurgical innovative medical devices in China, it provides comprehensive technological and product solutions for the treatment of brain diseases. Sinovation Medical has been honored with various accolades, including being recognized as a national high-tech enterprise and a national intellectual property advantage enterprise.
Sinovation Medical has independently developed nine products that have obtained Class III medical device registration certificates from the National Medical Products Administration (NMPA), with four of them approved through the special review channel for innovative medical devices. It has formed five major product lines, including the neurosurgical robot SR series, miniature neurosurgical robot Q300 series, neurosurgical navigation system NS series, intracranial electrode series, and magnetic resonance-guided laser ablation therapy system LS series. These products serve over 200 medical institutions nationwide, with the intracranial electrodes and neurosurgical robots ranking among the top in the domestic market share. Furthermore, the neurosurgical robot Sinobot X1 has also been appoved by the U.S. Food and Drug Administration (FDA), making it the only Chinese neurosurgical robotic system to obtain FDA approval.
Its wholly-owned subsidiary, Beijing Sinovation Medical Technology Co., Ltd. (aka Huake Hengsheng Medical Technology Co., Ltd., HKHS), is a globally renowned manufacturer of intracranial electrodes. It specializes in the research and development, production, and technical services of medical electrodes in the field of neurosurgery. It is the first company in China to achieve commercialization of intracranial EEG signal acquisition consumables and is recognized as a national high-tech enterprise. The company has obtained four Class III medical device registration certificates and the annual sales volume of intracranial electrodes reaches tens of thousands. These electrodes are widely used in over 200 Class A tertiary hospitals nationwide, making HKHS a leader in the domestic market and successfully replacing imported products as a whole.
We not only focus on technological innovation but also prioritize providing high-quality solutions for the healthcare industry. Our aim is to enhance the level of medical diagnosis and treatment, thereby driving continuous progress in medical technology. Sinovation Medical, in collaboration with the healthcare industry, is dedicated to shaping the future of intelligent healthcare.
| April | 1st domestic intracranial laser minimally invasive treatment product, the LITT system, obtained NMPA approval |
| May | completed Series D+ financing round |
| June | Second Prize of the Ministry of Education's Technical Invention Award |
| June | Sinobot X1 (aka SR1-3D), the world's first neurosurgical robot with 3D structured light technology received FDA approval |
| August | 1st domestical intracranial depth thermal coagulation electrode obtained NMPA approval |
| January | 1st domestic miniature neurosurgical robotic Q300 series obtained NMPA approval |
| April | Neurosurgical planning software entered the NMPA sepcial review channel for innovative medical devices |
| August | Recognized as a nationally acclaimed "Little Giants" enterprise |
| October | Recognized as a national intellectual property advantage enterprise |
| November | R&D of the next-generation LITT was included in the national key research and development program for the 14th Five-Year Plan |
| December | Completed Series D financing round; aquired intracranial electrode manufacturer Beijing Sinovation Medical Technology Co., Ltd. (aka Huake Hengsheng, HKHS) |
| January | Awarded 2nd Prize of the Chinese Medical Science and Technology Award |
| March | Recognized as one of the outstanding units in the first phase of the Ministry of Industry and Information Technology's Artificial Intelligence Industry Innovation Task |
| July | Neurosurgical robot SR series was selected for the "Excellent Domestic Medical Equipment Product Catalog" by the National Health Commission |
| October | Established 1st national neurosurgical robot training center |
| December | The First Prize of the Huaxia Medical Science and Technology Award; The cumulative surgical volume surpassed 10,000 cases |
| June | Completed strategic financing |
| July | Neurosurgical robot SR series was awarded the title of “the first major technical equipment” in Zhongguancun |
| December | Neurosurgical robot SR1-3D (aka Sinobot X1) obtained NMPA approval; Completed Series C financing round; Miniature neurosurgical robot Q300 series entered the NMPA special review channel for innovative medical devices; Neurosurgical robots achieved the highest market share, surpassing imports |
| September | Completed Series B financing round |
| December | Neurosurgical navigation system NS1 obtained NMPA approval; Undertook the task of technological research and development for "Neurosurgical Robots" from the Ministry of Industry and Information Technology; Neurosurgical navigation system received NMPA Class III medical device registration certificate; Laser ablation system (LITT) entered the NMPA special review channel for innovative medical devices |
| February | Completed Series A financing round |
| August | Neurosurgical robot successfully underwent clinical trials |
| September | R&D of surgical navigation received funding as part of the 13th Five-Year National Key Research and Development Program |
| December | Neurosurgical robot SR1 received NMPA Class III medical device registration certificate |
| March | Neurosurgical robot SR1 has entered the NMPA (former name: CFDA) special review channel for innovative medical device； Neurosurgical robot established a strategic partnership with PINS Medical through the CFDA special review for innovative medical devices |
| May | Neurosurgical robot entered the prototype development stage |
| Sinovation (Beijing) Medical Technology Co., Ltd. was established |
| The neurosurgical robot entered the experimental validation stage |
| The multimodal imaging-assisted stereotactic surgery planning system was successfully developed and deployed for clinical research, with technology reaching international leading levels |
| The research and development for the neurosurgical robot was initiated |
| HKHS obtained the first domestic registration certificate for intracranial depth brain electrode from CFDA |
| HKHS obtained the first domestic registration certificate for intracranial cortical electrode medical device |
| Tsinghua University collaborated with clinical institutions to carry out the research and development of the first generation of neurosurgical navigation system in China |
| Beijing Sinovation Medical Technology Co., Ltd. (aka Huake Hengsheng Medical Technology Co., Ltd., HKHS) was established |
| Started the production of the first domestic intracranial electrode |
| Our founders started research and development of the first domestic intracranial electrode |
